Intravenous Iron Drugs Market to Grow with a CAGR of 5.70% through 2030

Surge in research and development activities is expected to drive the Global Intravenous Iron Drugs Market growth in the forecast period, 2026-2030.

According to TechSci Research report, “Intravenous Iron Drugs Market - Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Intravenous Iron Drugs Market stood at USD 2.46 Billion in 2024 and is anticipated to grow with a CAGR of 5.70% through 2030. Initiatives taken by government based on intravenous iron drugs has led to favorable market conditions for the Global Intravenous Iron Drugs Market. Several factors contribute to the growth of various intravenous iron drugs products.

Innovative R&D initiatives have led to the introduction of next-generation IV iron therapies that offer improved safety profiles, higher single-dose administration, and reduced treatment frequency. These advancements are particularly valuable in managing chronic conditions such as chronic kidney disease, cancer-related anemia, and inflammatory bowel disease, where rapid and efficient iron replenishment is critical. The development of formulations such as ferric carboxymaltose, iron isomaltoside, and ferumoxytol exemplifies this trend, delivering enhanced clinical outcomes with reduced adverse reactions.

One of the most prominent examples is the incorporation of IV iron formulations into national anemia control strategies. Countries such as India, through initiatives like the Anemia Mukt Bharat (Anemia-Free India) program, have begun to scale up the use of parenteral iron, including ferric carboxymaltose and iron sucrose, for treating moderate to severe anemia in pregnant women. These programs often provide free or subsidized IV iron treatments in public hospitals and community health centers, making them more accessible to low-income populations.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Intravenous Iron Drugs Market”

The Global Intravenous Iron Drugs Market is segmented into product, application, regional distribution, and company.

Based on Product, Ferric Gluconate have emerged as the dominating segment in the Global Intravenous Iron Drugs Market in 2024. This is due to its well-established safety profile, clinical effectiveness, and widespread acceptance in the management of iron deficiency anemia, particularly among patients undergoing hemodialysis. One of the key factors driving the dominance of ferric gluconate is its proven track record in terms of safety. Compared to older formulations such as high-molecular-weight iron dextran, ferric gluconate is associated with a significantly lower incidence of severe hypersensitivity reactions, making it a preferred choice among healthcare providers.

Based on Region, Asia Pacific have emerged as the fastest growing region in the Global Intravenous Iron Drugs Market in 2024. This is driven by a combination of rising anemia prevalence, expanding healthcare infrastructure, and increasing awareness of intravenous treatment options. The region faces a high burden of iron deficiency anemia, particularly among women of reproductive age, pregnant women, and patients with chronic diseases, which is fueling demand for effective iron replacement therapies. Additionally, governments across countries such as India, China, and Indonesia are implementing national health programs focused on maternal and child health, which include screening and treatment for anemia.

Major companies operating in Global Intravenous Iron Drugs Market are:

• AMAG pharmaceuticals, Inc.
• Vifor Pharma Management Ltd.
• Daiichi Sankyo Company, Limited
• Rockwell Medical Inc.
• Allergan PLC
• Pfizer Inc.
• Nippon Shinyaku Co.
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Bausch Health Companies Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report

“Advanced nanocarriers, such as liposomes, polymeric nanoparticles, and carbohydrate-stabilized iron oxide complexes, are being utilized to encapsulate iron in forms that minimize free iron toxicity and reduce the likelihood of adverse reactions. These nanoformulations ensure a more stable iron-carbohydrate shell structure, resulting in a sustained and controlled release of iron into the bloodstream. This is particularly advantageous for patients with chronic conditions like kidney disease, cancer-related anemia, or inflammatory disorders who require high-dose iron with minimal infusion frequency”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Intravenous Iron Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Iron Dextran, Ferric Gluconate, Iron Sucrose, Ferric Carboxymaltos, Iron Isomaltoside 1000, Ferumoxytol), By Application (Intestinal Malabsorption Syndromes, Inflammatory Diseases, Gastrectomy/Bariatric Surgery, Anemia, Osier-Weber-Rendu Disease, Angiodysplasia, Pregnancy, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global Intravenous Iron Drugs Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Intravenous Iron Drugs Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]